SCHEMBL320949

SCHEMBL320949

Cc1c(Br)c2ccccn2c1C(=O)c1ccc(N)c(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.46
FNTA P49354 3/20 0.46
FNTB P49356 3/20 0.46
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
MAPK1 P28482 3/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 4/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572895 0.88 HTT (0.48) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL321101 0.88 KMT2A (0.43) HTTALDH1A1KMT2AMEN1MAPK1
SCHEMBL15067736 0.87 HTT (0.42) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL1573289 0.87 HTT (0.47) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL15067666 0.86 HTT (0.40) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL145931 0.84 HTT (0.45) HTTFNTAFNTBALDH1A1KMT2A
Sulfuric Acid SCHEMBL4494758 0.84 HTT (0.47) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL3954660 0.84 HTT (0.44) HTTFNTAFNTBALDH1A1KMT2A
Water SCHEMBL4620128 0.83 HTT (0.43) HTTFNTAFNTBALDH1A1KMT2A
SCHEMBL16340957 0.82 ALDH1A1 (0.39) HTTFNTAFNTBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797930-B1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-07-13 EP disclosed
US-9206177-B2 Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists SANOFI (FR) 2015-12-08 US disclosed
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof SANOFI (FR) 2014-12-25 US disclosed
EP-2797930-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-11-05 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
WO-2013098763-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-07-04 WO disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
CN-103080112-A Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI SA 2013-05-01 CN disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 EP disclosed
EP-2018165-A1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS Sanofi-Aventis (FR) 2009-01-28 EP disclosed
WO-2007080325-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof FGFR1, FGFR2, FGF2 HTT 4644/4885FNTA 3871/4885FNTB 2693/4885
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 HTT 1454/4885FNTA 2861/4885FNTB 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.